GlassScriptPhysician profile
Jordan L Natale
NPI 1922437342
$1,497.99
in general payments reported to CMS, 2019-2025
31 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.12 · 2022: $576 · 2023: $350 · 2024: $126 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.54 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $236.00 | 2024-2025 | Ogsiveo |
| Immunocore Limited | $137.76 | 2025 | Kimmtrak |
| Amgen INC. | $128.41 | 2022-2023 | Kyprolis |
| Astrazeneca Pharmaceuticals LP | $103.65 | 2022-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $83.99 | 2021 | |
| Merck Sharp & Dohme LLC | $65.05 | 2022-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $59.99 | 2022-2024 | |
| Janssen Biotech, INC. | $59.39 | 2022-2023 | Darzalex |
| Pharmacosmos Therapeutics INC. | $59.00 | 2022-2023 | Monoferric |
| Daiichi Sankyo INC. | $58.63 | 2022-2023 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $52.88 | 2022-2023 | Alunbrig |
| Foundation Medicine, INC. | $42.65 | 2022-2023 | |
| Puma Biotechnology, INC. | $37.09 | 2022-2023 | Nerlynx |
| Exelixis INC. | $37.00 | 2022 | |
| Lilly USA, LLC | $32.93 | 2022-2023 | Retevmo, Verzenio, Jaypirca |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.08 | 2022-2023 | |
| Genentech USA, INC. | $30.48 | 2022-2023 | Tecentriq |
| Adaptive Biotechnologies Corporation | $24.95 | 2022 | |
| Seagen INC. | $24.58 | 2023 | Tukysa |
| Incyte Corporation | $22.42 | 2022 | |
| Servier Pharmaceuticals LLC | $19.64 | 2023 | |
| Pfizer INC. | $19.38 | 2025 | |
| Glaxosmithkline, LLC. | $18.26 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.52 | 2022 | |
| Tersera Therapeutics LLC | $15.67 | 2022 | |
| Cti Biopharma Corp. | $14.39 | 2022 | |
| Abbvie INC. | $14.26 | 2023 | |
| Taiho Oncology, INC. | $14.20 | 2022 | |
| Coherus Oncology, INC. | $13.31 | 2023 | |
| Celgene Corporation | $12.30 | 2022 | |
| Tactile Systems Technology INC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Natale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.